Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

PURPOSE: Somatic mutations and copy number variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable therapeutic targets. We studied whether afatinib (an oral, irreversible inhibitor of the ErbB family) has activity in UC and if specific ERBB molecular alteratio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Choudhury, Noura J., Campanile, Alexa, Antic, Tatjana, Yap, Kai Lee, Fitzpatrick, Carrie A., Wade, James L., Karrison, Theodore, Stadler, Walter M., Nakamura, Yusuke, O’Donnell, Peter H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569685/
https://ncbi.nlm.nih.gov/pubmed/27044931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.3047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados